I
iRegene Therapeutics builds an AI-powered cell therapy platform using chemical induction to generate functional cells for age-related diseases like Parkinson's and vision impairment.
$294KSeries C1
A $300K Series C1 in 2026 suggests iRegene is either pre-revenue or early-traction with Chinese domestic investors—this is survival/runway funding, not growth capital. If you're building biotech infrastructure (assays, manufacturing, regulatory consulting), watch that China is still funding cell therapy despite Western caution on timelines; the real signal is whether they can move from chemical induction to clinical validation without needing $50M+ Series D.